Global Colorectal Cancer Market Size Likely to Surpass at a CAGR of 3.4% By 2033

As per the current market research conducted by the CMI Team, the global Colorectal Cancer Market size is expected to record a CAGR of 3.4% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 22,275.3 Million. By 2033, the valuation is anticipated to reach USD 30,095.9 Million.

Colorectal Cancer Market: Growth Factors and Dynamics

• Increasing Incidence and Prevalence: Colorectal cancer is one of the most prevalent cancers worldwide, with its incidence increasing globally. Factors such as aging populations, sedentary lifestyles, unhealthy dietary habits, and rising obesity rates contribute to the growing burden of colorectal cancer.

• Advancements in Screening and Early Detection: The development and adoption of advanced screening methods such as colonoscopies, fecal occult blood tests (FOBT), fecal immunochemical tests (FIT), and genetic testing have improved early detection rates. Early detection allows for timely intervention and better treatment outcomes, thereby driving market growth.

• Emergence of Targeted Therapies: The colorectal cancer market has witnessed significant advancements in targeted therapies, particularly for patients with specific molecular characteristics such as RAS or BRAF mutations. Drugs targeting these molecular alterations, such as EGFR inhibitors and BRAF inhibitors, have shown efficacy in subsets of patients, fueling market growth.

• Immunotherapy Revolution: Immunotherapy, particularly immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1), has transformed the treatment landscape for colorectal cancer. Checkpoint inhibitors have demonstrated promising results, especially in patients with microsatellite instability-high (MSI-H) tumors, leading to increased adoption and market expansion.

• Rising Healthcare Expenditure: Increased healthcare spending, especially in developed regions, supports investments in research and development efforts for new colorectal cancer treatments. Moreover, improvements in healthcare infrastructure, access to innovative therapies, and reimbursement policies contribute to market growth.

• Strategic Collaborations and Partnerships: Collaboration among pharmaceutical companies, academic institutions, and research organizations fosters innovation and accelerates the development of novel therapies and diagnostic tools. Partnerships facilitate the sharing of resources, expertise, and technology, driving the colorectal cancer market forward.

• Focus on Personalized Medicine: With an increasing understanding of the molecular mechanisms driving colorectal cancer, there’s a growing emphasis on personalized medicine approaches. Biomarker-based testing helps identify patients who are likely to benefit from specific treatments, leading to more targeted and effective therapies.

Colorectal Cancer Market: Partnership and Acquisitions

• In 2022, Chugai Pharmaceutical Co., Ltd. received regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the anti-HER2 monoclonal antibodies Perjeta and Herceptin, expanding their indications to include advanced or recurrent HER2-positive colon or rectal cancer not suitable for curative resection after chemotherapy.

• In 2022, Seagen’s partnership with Pfizer’s Array BioPharma involves the manufacture, development, and sale of Tukysa, a medication for breast and colorectal cancer. This collaboration strengthens Seagen’s position in the oncology market and expands treatment options for cancer patients.

Report Scope

Colorectal Cancer Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Colorectal Cancer Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Delayed Diagnosis and Treatment: During the peak of the COVID-19 pandemic, many healthcare systems prioritized resources for managing COVID-19 patients, leading to disruptions in routine screenings, diagnostic procedures, and treatment services for colorectal cancer. This delay in diagnosis and treatment initiation could result in more advanced stages of cancer at presentation, potentially impacting patient outcomes.

• Supply Chain Disruptions and Clinical Trials: Supply chain disruptions and restrictions on non-essential activities hindered the conduct of clinical trials and the availability of investigational drugs for colorectal cancer. Delays in patient enrollment, protocol deviations, and interruptions in trial procedures affected the advancement of novel therapies and research efforts in the field.

• Resumption of Screening and Diagnostic Services: As COVID-19 vaccination rates increase and healthcare systems stabilize, there’s a concerted effort to resume routine colorectal cancer screenings, diagnostic procedures, and treatment services. Health authorities and medical organizations are promoting awareness campaigns to encourage individuals to prioritize preventive screenings and seek medical attention for concerning symptoms.

• Telemedicine and Remote Monitoring: The adoption of telemedicine and remote monitoring technologies surged during the pandemic to facilitate virtual consultations, follow-up appointments, and patient monitoring. Incorporating telehealth into colorectal cancer care allows for continuity of care while minimizing the risk of exposure to infectious agents.

• Catch-Up Screening and Outreach Programs: Healthcare providers are implementing catch-up screening initiatives and outreach programs to target populations who missed or postponed colorectal cancer screenings due to the pandemic. Collaborative efforts between healthcare organizations, community centers, and advocacy groups aim to increase screening uptake, particularly among underserved and vulnerable populations.

• Investment in Research and Innovation: Despite the disruptions caused by COVID-19, investment in colorectal cancer research and innovation remains crucial for advancing treatment options and improving patient outcomes. Pharmaceutical companies, academic institutions, and research organizations continue to pursue novel therapeutic strategies, biomarker discovery, and precision medicine approaches to address unmet needs in colorectal cancer care.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Colorectal Cancer Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Colorectal Cancer Market:

• Hoffmann-La Roche Ltd
• Merck & Co. Inc.
• Bayer AG
• Amgen Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Novartis International AG
• AstraZeneca PLC
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Company Limited
• Johnson & Johnson
• Others

The Colorectal Cancer Market is segmented as follows:

By Type of Treatment

• Surgery
• Chemotherapy
• Radiation Therapy
• Targeted Therapy
• Immunotherapy
• Combination therapies

By Molecular Characteristics

• Microsatellite stable (MSS)
• Microsatellite instability-high (MSI-H)
• RAS mutation status (KRAS, NRAS)
• BRAF mutation status
• HER2 status

By Route of Administration

• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America